Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Newly formed Radcliffe Department of Medicine launches

Events Research

The Radcliffe Department of Medicine (RDM) is today (25 March 2013) hosting its Inaugural Symposium. RDM, which is part of the University of Oxford’s Medical Sciences Division, brings together about 500 staff from several research areas.

Radcliffe Department of Medicine logoThe symposium showcased the breadth of research conducted within RDM and gave researchers from across the department the opportunity to hear about their colleagues work and share ideas. In an effort to increase internal collaborations, RDM has developed an innovative funding scheme in which researchers collaborating across the department will be eligible to apply for additional funding. 

The Radcliffe Department of Medicine was formed in 2012 through an amalgamation of the Departmentof Cardiovascular Medicine, the Oxford Centre for Diabetes, Endocrinology and Metabolism (OCDEM), the majority of research groups from the MRC Weatherall Institute of Molecular Medicine (WIMM), the Nuffield Department of Clinical Laboratory Sciences, the Oxford Acute Vascular Imaging Centre (AVIC) and the academic groups in Geratology and Stroke who were formerly members of the Nuffield Department of Medicine,  Experimental Medicine Division. These latter groups, together with a new programme in Experimental Therapeutics and the new Centre for the Advancement of Sustainable Medical Innovation (CASMI), will now constitute the Investigative Medicine Division (IMD) of RDM.

Head of Department, Professor Hugh Watkins commented: “The motivation for forming the RDM was to bring groups together that could add value to one another and I think the breadth and quality of research presented today shows just how great the potential is."

Links: 

Radcliffe Department of Medicine

Medical Sciences Division

Similar stories

Latest data on immune response to COVID-19 reinforces need for vaccination, says Oxford-led study

A new study led by the University of Oxford has found that previous infection, whether symptomatic or asymptomatic, does not necessarily protect you long-term from COVID-19, particularly against new Variants of Concern.

First trimester placental scan - Artificial Intelligence in Health and Care Award

A first trimester 3D placental ultrasound scan which can predict fetal growth restriction and pre-eclampsia, could become part of a woman's routine care thanks to a new Artificial Intelligence in Health and Care Award.

Impaired antibody response to COVID-19 vaccination in patients with myeloid blood cancers

Oxford researchers have found that antibody responses to the first doses of COVID-19 vaccine in people with chronic myeloid blood cancers are not as strong as those among the general population.

Treating Needle Fears May Reduce COVID-19 Vaccine Hesitancy Rates by 10%

A new large-scale study shows that a quarter of the UK adult population screens positive for a potential injection phobia.

RECOVERY trial Regeneron’s monoclonal antibody combination reduces deaths for hospitalised COVID-19 patients

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) trial has demonstrated that the investigational antibody combination developed by Regeneron reduces the risk of death when given to patients hospitalised with severe COVID-19 who have not mounted a natural antibody response of their own.

Major new study could help protect millions of people with type 2 diabetes from cardiovascular disease

A new study led by the Nuffield Department of Population Health at the University of Oxford will research whether a daily tablet could help protect the millions of people worldwide with type 2 diabetes from developing cardiovascular disease.